Evaluation of Anti-neutrophil Cytoplasm Antibodies Test

Launched by SOHAG UNIVERSITY · Jan 19, 2021

Keywords

ClinConnect Summary

To evaluate the performance of the recommended strategy for the detection of ANCA based on screening with antigen specific immunoassays on a number of AAV patients and relevant disease controls (i. e., patients for whom ANCA would be requested in the context of small-vessel vasculitis such as patients with infections, drug-induced diseases, connective tissue disease, etc.).

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • .All patients included must be older than 18 years and able to give informed consent.
• • Classification criteria and nomenclature for AAV are from the American College of Rheumatology
• • Serum sampling should be done before initiation of immunosuppressive treatment or no later than 2 weeks after onset of low-medium dose of immunosuppressive treatment (but this should be documented)
• Exclusion Criteria:
• • .Patients younger than 18 years old